EP
MRSN

Eversept Partners’s Mersana Therapeutics MRSN Stock Holding History

Eversept Partners’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,600
Closed -$2.61M – 66
2020
Q3 		$2.61M Buy
+5,600
New +$2.83M 0.58% 31

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Eversept Partners's MRSN Position: Q4 2020 in Review

Eversept Partners sold out of Mersana Therapeutics (MRSN) in Q4 2020, closing a stake of 5,600 shares — an estimated $2.61M sold.

Eversept Partners first reported a position in MRSN in Q3 2020 and held it in 1 quarter. The position peaked at $2.61M in Q3 2020. 151 funds tracked by Wall St. Rank hold MRSN as of Q4 2020.

  • Eversept Partners reported no remaining Mersana Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Eversept Partners sold 5,600 Mersana Therapeutics shares in Q4 2020, an estimated $2.61M.
  • Eversept Partners first reported a position in Mersana Therapeutics in Q3 2020 and held it in 1 quarter.
  • Eversept Partners's Mersana Therapeutics position peaked at $2.61M in Q3 2020.
  • 151 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2020.

Based on Eversept Partners's 13F filing for Q4 2020, filed 16 Feb 2021.